PMID- 18483377 OWN - NLM STAT- MEDLINE DCOM- 20080818 LR - 20210102 IS - 1078-0432 (Print) IS - 1078-0432 (Linking) VI - 14 IP - 10 DP - 2008 May 15 TI - Postoperative adjuvant dendritic cell-based immunotherapy in patients with relapsed glioblastoma multiforme. PG - 3098-104 LID - 10.1158/1078-0432.CCR-07-4875 [doi] AB - PURPOSE: To investigate the therapeutic role of adjuvant vaccination with autologous mature dendritic cells (DC) loaded with tumor lysates derived from autologous, resected glioblastoma multiforme (GBM) at time of relapse. EXPERIMENTAL DESIGN: Fifty-six patients with relapsed GBM (WHO grade IV) were treated with at least three vaccinations. Children and adults were treated similarly in three consecutive cohorts, with progressively shorter vaccination intervals per cohort. Feasibility and toxicity were assessed as well as effect of age, extent of resection, Karnofsky Performance Score, and treatment cohort on the progression-free (PFS) and overall survival (OS) using univariable and multivariable analysis. RESULTS: Since the prevaccine reoperation, the median PFS and OS of the total group was 3 and 9.6 months, respectively, with a 2-year OS of 14.8%. Total resection was a predictor for better PFS both in univariable analysis and after correction for the other covariates. For OS, younger age and total resection were predictors of a better outcome in univariable analysis but not in multivariable analysis. A trend to improved PFS was observed in favor of the faster DC vaccination schedule with tumor lysate boosting. Vaccine-related edema in one patient with gross residual disease before vaccination was the only serious adverse event. CONCLUSION: Adjuvant DC-based immunotherapy for patients with relapsed GBM is safe and can induce long-term survival. A trend to PFS improvement was shown in the faster vaccination schedule. The importance of age and a minimal residual disease status at the start of the vaccination is underscored. FAU - De Vleeschouwer, Steven AU - De Vleeschouwer S AD - Department of Neurosurgery, Catholic University of Leuven, Leuven, Belgium. steven.devleeschouwer@uz.kuleuven.ac.be FAU - Fieuws, Steffen AU - Fieuws S FAU - Rutkowski, Stefan AU - Rutkowski S FAU - Van Calenbergh, Frank AU - Van Calenbergh F FAU - Van Loon, Johannes AU - Van Loon J FAU - Goffin, Jan AU - Goffin J FAU - Sciot, Raf AU - Sciot R FAU - Wilms, Guido AU - Wilms G FAU - Demaerel, Philippe AU - Demaerel P FAU - Warmuth-Metz, Monika AU - Warmuth-Metz M FAU - Soerensen, Niels AU - Soerensen N FAU - Wolff, Johannes E A AU - Wolff JE FAU - Wagner, Sabine AU - Wagner S FAU - Kaempgen, Eckhart AU - Kaempgen E FAU - Van Gool, Stefaan W AU - Van Gool SW LA - eng PT - Clinical Trial PT - Journal Article PT - Research Support, Non-U.S. Gov't PL - United States TA - Clin Cancer Res JT - Clinical cancer research : an official journal of the American Association for Cancer Research JID - 9502500 RN - 0 (Antigens, Neoplasm) RN - 0 (Cancer Vaccines) SB - IM MH - Adolescent MH - Adult MH - Aged MH - Antigens, Neoplasm/immunology/*therapeutic use MH - Brain Neoplasms/*therapy MH - Cancer Vaccines/immunology/*therapeutic use MH - Child MH - Dendritic Cells/*immunology MH - Disease-Free Survival MH - Female MH - Glioblastoma/mortality/*therapy MH - Humans MH - Kaplan-Meier Estimate MH - Male MH - Middle Aged MH - Neoplasm Recurrence, Local/mortality/*therapy MH - Postoperative Period EDAT- 2008/05/17 09:00 MHDA- 2008/08/19 09:00 CRDT- 2008/05/17 09:00 PHST- 2008/05/17 09:00 [pubmed] PHST- 2008/08/19 09:00 [medline] PHST- 2008/05/17 09:00 [entrez] AID - 14/10/3098 [pii] AID - 10.1158/1078-0432.CCR-07-4875 [doi] PST - ppublish SO - Clin Cancer Res. 2008 May 15;14(10):3098-104. doi: 10.1158/1078-0432.CCR-07-4875.